Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04361058
Title Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.